Joao Fogacci

Happy to share our recent paper, in which we show that DKC1 is both a therapeutic target and a diagnostic biomarker in colorectal cancer. DKC1 is a critical part of the telomerase complex, and when elevated, it fuels cancer progression. Link: nature.com/articles/s4146…

🦓 MEN1 vs VHL vs sporadic PanNETs: does it matter in post-pancreatectomy outcomes? 👥1527 ✅Same postop morbidity ✅Same PFS & OS 🔑 Syndrome status doesn't change periop risk ⚠️But, disease & indications not the same: can they really be compared? tinyurl.com/2k7hwbc8

Diagnosis and management of gastric premalignant conditions - summary of ACG 2025 guidelines 📍

🫀 HCC Recurrence After Liver Transplantation Remains a Major Challenge Although liver transplantation offers curative potential for HCC, post-transplant recurrence is still associated with poor outcomes. 🔗 f.oaes.cc/xmlpdf/780316d… #LiverTransplantation #TransplantOncology

Diagnosis, treatment and prognosis of simple hepatic cyst: Clinical practice guideline 🌷doi.org/10.14701/ahbps… Ann Hepatobiliary Pancreat Surg 2025;29(3). Seoung Yoon Rho #Cysts #LiverDisease #PracticeGuideline

🧠📊 Cabo+nivo+ipi in PD NECs ✔️ Durable responses possible: 2 PRs lasting 27 & 17 months ⚠️ Overall activity limited: ORR 12.5% mPFS 2.7 months 🔹 Grade 3-4 TRAEs: 56% 💡 Study stopped early → regimen not supported for further development 🔗 academic.oup.com/oncolo/article… @myESMO @GrupoGetne

🆕June issue now online 👉mCRC: ESMO Clinical Practice Guideline 👉PHERGain-2: trastuzumab–pertuzumab and T-DM1 in HER2+ eBC 👉COSMIC-313: Cabo+nivo and ipilimumab in previously untreated, adv RCC annalsofoncology.org/issue/S0923-75…

Seeing this level of discordance even among HER2 3+ cases is surprising. Pathologists, please don’t get mad🙂 but digital pathology and AI support in HER2 ( and the others🫣) assessment are starting to feel like a real necessity rather than an option. aacrjournals.org/clincancerres/…

🧬 NTRK gene fusions across cancers: large compendium mapping fusion partners and tumor types for TRK inhibitor precision oncology! @JCOPO_ASCO ascopubs.org/doi/full/10.12… ▪️ 358 distinct NTRK fusion–tumor pairings identified ▪️ 229 unique fusion partners across 25 tumor types ▪️ CNS tumors and sarcomas showed the highest fusion diversity ▪️ ETV6::NTRK3 remained the most broadly distributed fusion ▪️ Highlights the need for pan-tumor, partner-agnostic fusion testing Finding an NTRK fusion is about knowing the dance partner too 💃 @OncoAlert @OncoReporte @myESMO @_SEOM @ASCO

Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients with Gastroesophageal Adenocarcinoma. Co-authored by @ssihag_MSK, @Sam_Cytryn and @MSK_Thoracic. Read the full article. bit.ly/3P67nIW

10 Must-Read Posts in GI Oncology | 𝗦𝗲𝗰𝗼𝗻𝗱 𝗪𝗲𝗲𝗸 𝗼𝗳 𝗠𝗮𝘆 🔑 Highlights: • ATM-deficient PDAC and TGF-β-driven CAF reprogramming • BRAF subclasses and RAS co-mutations in CRC • HCC cure modeling with immunotherapy • SABER trial: SBRT + mFOLFIRINOX in LAPC • irAEs and post-transplant rejection risk in HCC • CAF-driven basal-like pancreatic cancer biology • NordICC long-term CRC screening outcomes • Multi-omic profiling in biliary tract cancers • AI-based tumor bud segmentation in CRC • FIT-based CRC screening strategies in Mexico City 💡 Translational biology, immunotherapy, AI, molecular profiling, and screening strategies continue to shape the future of GI oncology. @NelsonDusetti @IbrahimSahinMD1 @NaultJc @changhoon_yoo @ArndtVogel @Aiims1742 @PaulaMorgane @Metin4020 @feralaes 📎oncodaily.com/not-to-miss/gi… #OncoDaily #GIOncology

Postoperative Hepatic Arterial Infusion With Oxaliplatin After Surgery of Four or More Colorectal Liver Metastases: A Randomized Phase II Trial @JCO_ASCO doi.org/10.1200/JCO-25… 👉mh-RFS 25 vs 12 mo 👉mRFS 14 vs 9 mo 👉mOS 74 vs 57 mo 🧐seems to be promising and safe approach

Invited commentary on: “Post-surgical ctDNA as a prognostic biomarker for relapse of resected pancreatic ductal adenocarcinoma” sciencedirect.com/science/articl…

🔥⏳ The countdown to #ASCO26 has officially started. Here are the Oral & Rapid Oral Abstract titles in #gastroesophageal, #pancreaticcancer #BTC and #HCC tumors 👀 A lot of highly anticipated studies coming this year. #GIoncology @OncoAlert @Larvol

Excited to share our colleague Dr. Seguchi’s latest work published in Clinical Cancer Research! A multiomic analysis revealing the clinical and immunologic implications of MTAP loss in solid tumors. 🔗doi.org/10.1158/1078-0… @CCR_AACR @OncoAlert

Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649 @Annals_Oncology doi.org/10.1016/j.anno… 👉5-yr OS 16% vs 6% 👉5-yr PFS 10% vs 6% 🧐great to see more long-term OS @myESMO @ASCO

Interventions to Improve Clinician Implementation of and Patient Adherence to Recommendations on Geriatric Assessment and Management: A Scoping Review. agsjournals.onlinelibrary.wiley.com/doi/10.1111/jg… @AGSJournal @AmerGeriatrics #Geriatrics #GeriOnc @myCARG

When Does Acceptable Become Unacceptable? Toxicities of Emerging Therapies | American Society of Clinical Oncology Educational Book ascopubs.org/doi/10.1200/ED…

Response to the Letter to the Editor "Organ Preservation in Locally Advanced Rectal Cancer After Total Neoadjuvant Therapy With Endoscopic Submucosal Dissection" Read the authors' response now in #DCRJournal: bit.ly/3QXDPhb

Continuation of First-Line Systemic Therapy with Progression-Directed Radiotherapy in Patients with Oligoprogressive Hepatocellular Carcinoma: A Multicenter, Single-Arm, Phase II Trial | Clinical Cancer Research | American Association for Cancer Research aacrjournals.org/clincancerres/…